Robeco Institutional Asset Management B.V. Purchases 140,966 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Robeco Institutional Asset Management increased its position in Regeneron by 116.6%, buying 140,966 shares to hold 261,850 shares (about 0.25% of the company) valued at roughly $202.1 million per its latest 13F filing.
• Insiders sold 3,774 shares in the last quarter (about $2.94 million), including SVP Jason Pitofsky and Director Huda Zoghbi, leaving company insiders with approximately 7.02% ownership.
• Several analysts raised ratings and targets — Bank of America upgraded to a buy ($860), Barclays initiated overweight ($923) and JPMorgan raised its target to $950 — giving an average MarketBeat price target of $811.96 after Regeneron beat Q4 EPS and raised its quarterly dividend to $0.94.

Robeco Institutional Asset Management B.V. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 116.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 261,850 shares of the biopharmaceutical company's stock after purchasing an additional 140,966 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.25% of Regeneron Pharmaceuticals worth $202,114,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in REGN. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, FNY Investment Advisers LLC bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $38,000. 83.31% of the stock is currently owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company's stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,774 shares of company stock valued at $2,942,738. Company insiders own 7.02% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on REGN. Bank of America upgraded shares of Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and upped their price target for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a "sector perform" rating in a report on Monday, March 2nd. Barclays assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, March 6th. They issued an "overweight" rating and a $923.00 target price on the stock. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an "equal weight" rating in a research note on Friday. Finally, JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an "overweight" rating in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $811.96.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $748.87 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The company has a market capitalization of $79.17 billion, a P/E ratio of 18.02, a P/E/G ratio of 1.99 and a beta of 0.40. The company's 50-day simple moving average is $767.42 and its two-hundred day simple moving average is $720.05. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts' consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the firm earned $12.07 EPS. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.